SARC044: NOW RECRUITING FOR PATIENTS

About SARC
Together We Can Change Patient Outcomes
Impact

Team

News

Newsletter

History

Financials
Research
Catalyzing Scientific and Clinical Progress
Active Clinical Trials

Completed Clinical Trials

Publications

Funding Opportunities

Career Development Award

Catalyst Program

Trial Design

Submit a Concept
Meetings
Collaborating to Cure Sarcoma
SARC Meeting Before ASCO

SARC Meeting As Part of CTOS

Past Meetings

SASS Conference
Resources
Resources for Professionals, Patients and Families
Find a Sarcoma Center

Biospecimen Bank

Clinical Data Repository

Imaging Resources

SARC Talk Podcast

Tumor Board

Why Choose a Clinical Trial?

What is sarcoma?

Bone Sarcoma Types

Soft Tissue Sarcoma Subtypes
Partner With Us
Investing in the Future of Sarcoma Research
For Donors & Supporters

For Industry

For Patients & Caregivers

Research Advocacy Council

For Researchers & Clinicians

Tumor Board

For Sarcoma Centers

Sarcoma Centers Directory Application

SARC Consortium Members

Sign Up For News
Contact Us
Donate

Search

Home » SARC Centers » Gustave Roussy

Gustave Roussy

November 11, 2021

Share:

Join OUR community

Stay up-to-date on clinical trials and learn from our team of sarcoma experts.

About Sarc

SARC (Sarcoma Alliance for Research through Collaboration) is a U.S.-based 501 (c)(3) non-profit cancer research organization dedicated to the development and support of research for the prevention, treatment, and cure of sarcoma – a cancer of the bone and connective tissues of the body.

P.O. Box 406 | Ann Arbor, MI 48106
Phone: 734.930.7600 | Fax: 734.930.7557 | Email: sarc@sarctrials.org

Financial Conflict of Interest Policy

For:
DONORS & SUPPORTERS
INDUSTRY
PATIENTS & CAREGIVERS
RESEARCHERS & CLINICIANS
SARCOMA CENTERS

Back to top

Stay in touch

We respect your privacy and are committed to protecting the confidentiality of those who use our web site or interact with us online. SARC does not share, sell, or exchange any information about visitors, donors, newsletter recipients, nor our constituents with any third party.